

JUN 02 2005

002

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete If Known</i>	
				Application Number	10/691,528
				Filing Date	October 24, 2003
				First Named Inventor	Wilhelm et al
				Group Art Unit	1623
				Examiner Name	Matthew L. Fedowitz
				Confirmation No.	7396
Sheet	1	of	1	Attorney Docket Number	2923-576

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
/KC/	1.	Onkologie 2004/05, Chemotherapie		
/KC/	2.	Breastcancer.org, <u>Hormonal Therapy</u> , <u>www.breastcancer.org/tre_sys_idx.html</u> , July 1, 2005		
/KC/	3.	National Cancer Institute, Cancer Facts, Tamoxifen: Questions and Answers, May 13, 2002.		
Examiner Signature	/Kendra Carter/		Date Considered	12/27/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.